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Cardiovascular disease is the leading cause of mor-
bidity and mortality in patients with hemodialysis,
presumably due to accumulation of risk factors for
atherosclerosis [1–3]. Identification of patients at high
risk for cardiovascular disease and requiring aggres-
sive preventive and interventional strategies is an
initial and essential step in managing patients with
hemodialysis.
The ankle-brachial index (ABI) was reported to be
a good marker for atherosclerosis and useful in the
diagnosis of peripheral artery disease. An ABI<0.9 has
been used to identify peripheral artery occlusive dis-
ease (PAOD) in clinical practice and epidemiologic
studies [4–6]. As previously reported, high preva-
lence of PAOD was found using ABI in hemodialysis
patients [7–9]. In addition, ABI ≥ 1.3 is considered to
indicate medial artery calcification [10]. Patients with
abnormally high ABI also had poor prognosis for all-
cause and cardiovascular mortality in hemodialysis
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Ankle-brachial index (ABI) is a marker for peripheral artery disease and can predict mortality in
hemodialysis patients. However, it is seldom studied in southern Taiwan, an area with high
prevalence of end-stage renal disease (ESRD). The aim of this study was to investigate the preva-
lence and associated risk factors for peripheral artery disease in the ESRD population in a hospital.
All routine hemodialysis patients in one regional hospital were included except for six patients
who refused ABI examinations and four patients with atrial fibrillation. Finally, 225 patients
formed our study group. ABI was measured using an ABI-form device (Colin VP1000). The
prevalence of ABI < 0.9 and ≥ 1.3 was 15.6% and 5.8%, respectively. ABI < 0.9 was independently
associated with advanced age (p = 0.027), increased pulse pressure (p = 0.005), increased hemat-
ocrit (p = 0.008) and decreased serum albumin level (p = 0.009). In addition, ABI ≥ 1.3 was signifi-
cantly associated with diabetes mellitus (p = 0.019). This study demonstrated the associated risk
factors of peripheral artery disease in patients with hemodialysis in a hospital. ESRD patients of
advanced age and with increased pulse pressure, increased hematocrit and decreased serum
albumin level had a relatively high risk for ABI < 0.9 and patients with diabetes had a relatively
high risk for ABI ≥ 1.3.
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patients [9]. However, little is known about the preva-
lence and associated risk factors of peripheral artery
disease in an end-stage renal disease (ESRD) popula-
tion in southern Taiwan [11]. The aim of this study was
to evaluate the prevalence and associated risk factors
for peripheral artery disease in ESRD patients under-
going hemodialysis in southern Taiwan.
METHODS
Study patients and design
The study was conducted in one regional hospital in
southern Taiwan. All routine hemodialysis patients
in this hospital were included except for six patients
who refused ABI examinations and four patients with
atrial fibrillation. Finally, 225 patients (98 males, 127
females) formed our hemodialysis group. The protocol
was approved by our Institutional Review Board and
all enrolled patients gave written informed consent.
Hemodialysis
All hemodialysis patients underwent their routine
hemodialysis three times a week using a Toray 321
machine (Toray Medical Company, Tokyo, Japan).
Each session of hemodialysis lasted for 3–4 hours and
was performed using a dialyzer with a blood flow
rate of 250–300 mL/minute and dialysate flow rate of
500 mL/minute.
ABI measurement
Measurements of ABI were made using an ABI-form
device (VP1000; Colin Co. Ltd., Komaki, Japan), which
automatically and simultaneously measures blood
pressure (BP) in both arms and ankles using an oscil-
lometric method [12–14]. An ABI < 0.9 is 95% sensitive
and 100% specific for angiographically documented
PAOD in identifying healthy individuals [15]. ABI
measurements were made 10–30 minutes before hemo-
dialysis. Occlusion and monitoring cuffs were placed
tightly around the upper arm without blood access
and on both sides of the lower extremities in the supine
position. ABI was calculated as the ratio of ankle sys-
tolic BP divided by arm systolic BP, with only the
lower value of the ankle systolic BP used for calcu-
lation. ABI measurements were done once in each
patient. An ABI ≥ 0.9 and < 1.3 was considered normal,
and patients were diagnosed as having peripheral
artery disease if ABI was < 0.9 or ≥ 1.3.
Collection of demographic, medical, and
laboratory data
Demographic and medical data including age, gen-
der, smoking history and comorbid conditions were
obtained from medical records and interviews with
patients. Body mass index was calculated as the ratio
of weight in kilograms divided by the square of
height in meters. Comorbid conditions were defined
as follows. Study subjects were defined as having
diabetes mellitus (DM) if the claimed data had ICD-9
code 250.00 to 250.90, or the fasting blood glucose
level was greater than 126 mg/dL, or hypoglycemic
agents were used to control blood glucose levels. 
A similar definition was applied to hypertension with
an ICD-9 code of 401.9, diagnosed by a physician, 
a systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg,
or using antihypertensive medications irrespective 
of BP. Cerebrovascular disease was defined as a his-
tory of cerebrovascular accident including cerebral
bleeding and infarction. Coronary artery disease was
defined as a history of angina, ischemic electrocar-
diogram change, old myocardial infarction, or having
undergone coronary bypass surgery or angioplasty.
Laboratory data were obtained from fasting blood
samples using an autoanalyzer (COBAS Integra 400;
Roche Diagnostics GmbH, Mannheim, Germany).
High-sensitivity C-reactive protein was measured by
commercially available kits (Dade Behring Marburg
GmbH, Marburg, Germany). Serum intact parathyroid
hormone (PTH) concentration was evaluated using a
commercially available two-sided immunoradiometric
assay (CIS Bio International, Gif Sur Yvette, France).
Blood samples were obtained within 1 month of enrol-
ment. Kt/V was evaluated monthly as a marker of
dialysis efficiency, and was determined according to
the procedure of Gotch [16].
Statistical analysis
Statistical analysis was performed using SPSS version
12.0 (SPSS Inc., Chicago, IL, USA) for Windows. Data
are expressed as percentage or mean ± standard devi-
ation. Differences between groups were determined by
the χ2 test for categorical variables or the independ-
ent t test for continuous variables. Logistic regression
was used to identify the risk factors associated with
ABI < 0.9 or ≥ 1.3. Significant variables in the univari-
ate analysis were further analyzed by multivariate
analysis. A significant difference was considered when
the p value was less than 0.05.
RESULTS
The mean age of the 225 patients was 58.7 ± 13.0 years.
The prevalence of ABI < 0.9 and ≥ 1.3 was 15.6% and
5.8%, respectively. The differences between patients
with normal and pathologic ABI are shown in Table 1.
Compared with patients with normal ABI, patients
with ABI < 0.9 were found to be of an older age (p <
0.001), have higher prevalence of DM (p < 0.001), coro-
nary artery disease (p=0.008) and cerebrovascular dis-
ease (p = 0.008), lower diastolic BP (p = 0.049), higher
pulse pressure (p < 0.001), lower serum albumin (p =
0.001), higher fasting glucose (p = 0.043), lower high-
density lipoprotein cholesterol (p < 0.001), and higher
hematocrit levels (p = 0.026). In addition, patients with
ABI ≥ 1.3 had a higher prevalence of DM (p = 0.014)
than those with normal ABI.
Table 2 shows the determinants of ABI < 0.9 among
the study patients. In the univariate regression analy-
sis, ABI < 0.9 was found to be significantly associated
with advanced age (p < 0.001), the presence of DM (p =
0.001), a history of coronary artery disease (p = 0.007)
and cerebrovascular disease (p=0.012), increased pulse
pressure (p = 0.030), decreased serum albumin level
(p = 0.002), increased fasting glucose (p = 0.030), de-
creased high-density lipoprotein cholesterol (p=0.011),
and increased hematocrit level (p = 0.019). After mul-
tiple logistic regression analysis, ABI < 0.9 was posi-
tively associated with age (p = 0.027), pulse pressure
(p = 0.005), and serum hematocrit level (p = 0.008), but
negatively associated with serum albumin level
(p = 0.009).
We also analyzed the determinants of ABI ≥ 1.3 in
study patients, and found that DM (hazard ratio, 4.733;
ABI in hemodialysis patients
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Table 1. Comparison of patients with a normal ABI (between 0.9 and 1.3) and a pathologic one
ABI ≥ 0.9 to 1.3 ABI < 0.9 ABI ≥ 1.3 All patients 
(n = 177) (n = 35) (n = 13) (n = 225)
ABI 1.12 ± 0.10 0.72 ± 0.14* 1.38 ± 0.09* 1.08 ± 0.19
Age (yr) 57.4 ± 12.8 66.9 ± 9.7* 54.6 ± 14.6 58.7 ± 13.0
Male gender (%) 45.8 31.4 46.2 43.6
Duration of dialysis (mo) 55.6 ± 47.1 62.2 ± 51.7 51.0 ± 36.5 56.4 ± 47.2
Smoking history (%) 28.3 22.9 23.1 27.1
Diabetes mellitus (%) 33.3 68.6* 69.2† 40.9
Hypertension (%) 67.8 77.1 84.6 70.2
Coronary artery disease (%) 26.0 48.6† 38.5 30.7
Cerebrovascular disease (%) 7.9 22.9† 0 9.8
Systolic BP (mmHg) 143.3 ± 24.2 151.8 ± 34.4 139.2 ± 22.1 144.3 ± 25.9
Diastolic BP (mmHg) 79.5 ± 14.9 73.7 ± 18.3† 76.2 ± 20.1 78.5 ± 15.8
Pulse pressure (mmHg) 63.8 ± 16.3 78.1 ± 19.2* 63.0 ± 15.8 65.8 ± 17.4
Body mass index (kg/m2) 23.9 ± 3.4 24.0 ± 4.3 22.7 ± 3.4 23.8 ± 3.5
Laboratory parameters
Albumin (g/dL) 3.8 ± 0.3 3.7 ± 0.3† 3.8 ± 0.3 3.8 ± 0.3
Fasting glucose (mg/dL) 115.9 ± 52.6 140.2 ± 63.5† 124.9 ± 46.2 120.2 ± 54.5
Triglyceride (mg/dL) 167.3 ± 126.7 161.7 ± 91.6 185.3 ± 174.0 167.5 ± 124.6
Cholesterol (mg/dL) 184.4 ± 41.9 177.3 ± 44.4 170.5 ± 42.5 182.5 ± 42.3
HDL cholesterol (mg/dL) 47.4 ± 15.1 39.9 ± 9.3* 43.8 ± 14.1 46.1 ± 14.5
LDL cholesterol (mg/dL) 88.5 ± 27.6 89.5 ± 23.8 74.0 ± 19.7 87.8 ± 26.8
Hematocrit (%) 30.6 ± 3.1 32.0 ± 3.8† 29.0 ± 3.8 30.7 ± 3.3
Calcium (mg/dL) 9.8 ± 0.8 9.8 ± 0.8 10.0 ± 0.7 9.8 ± 0.8
Phosphate (mg/dL) 4.8 ± 1.2 4.8 ± 1.2 5.2 ± 1.0 4.8 ± 1.2
Uric acid (mg/dL) 7.6 ± 1.5 7.7 ± 1.8 8.3 ± 1.5 7.6 ± 1.5
PTH (pg/mL) 514.2 ± 470.6 450.2 ± 321.8 754.9 ± 523.3 516.4 ± 455.5
C-reactive protein (mg/L) 0.7 ± 1.3 0.9 ± 1.0 0.8 ± 1.3 0.73 ± 1.23
Kt/V 1.3 ± 0.2 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.2
*p < 0.001 and †p < 0.05 compared with ABI ≥ 0.9–1.3. ABI = ankle-brachial index; BP = blood pressure; HDL = high-density lipoprotein;
LDL = low-density lipoprotein; PTH = parathyroid hormone.
p = 0.019) was significantly correlated with ABI ≥ 1.3
in the multivariate analysis.
DISCUSSION
In the present study, we evaluated the prevalence
and associated risk factors for peripheral artery dis-
ease in 225 hemodialysis patients in Taiwan. We
found that ABI < 0.9 was positively associated with
age, pulse pressure and hematocrit, but negatively
associated with serum albumin level. In addition, the
presence of DM was independently associated with
ABI ≥ 1.3.
Recently, PAOD has been reported to be prevalent
in hemodialysis patients and influences their mortality
[17,18]. In our study, the prevalence of PAOD, de-
fined as ABI < 0.9, was 15.6%, which was close to that
(16.5%) obtained from a large-scale epidemiologic sur-
vey conducted by Ono et al [9]. Previous studies have
identified several risk factors for PAOD in hemodial-
ysis patients, including old age, DM, a history of car-
diovascular disease and cerebrovascular disease, low
albumin level and high pulse pressure [9,19–22]. In the
current study, we confirmed most of these factors,
including advanced age, increased pulse pressure and
lower albumin level. An interesting finding was the
strong correlation between ABI < 0.9 and increased
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Table 2. Determinants of ankle-brachial index < 0.9 in study patients
Univariate Multivariate
Parameter
OR (95% CI) p OR (95% CI) p
Age (per 1 year) 1.073 (1.036–1.112) < 0.001 1.055 (1.006–1.106) 0.027
Male vs. female 0.543 (0.252–1.170) 0.119 – –
Smoking (ever vs. never) 0.766 (0.327–1.792) 0.539 – –
Diabetes mellitus 3.914 (1.807–8.478) 0.001 1.878 (0.618–5.701) 0.266
Hypertension 1.520 (0.652–3.545) 0.332 – –
Coronary artery disease 2.574 (1.233–5.376) 0.007 1.649 (0.615–4.416) 0.320
Cerebrovascular disease 3.725 (1.428–9.713) 0.012 2.071 (0.567–7/571) 0.271
Duration of dialysis (per 1 month) 1.003 (0.996–1.010) 0.427 – –
Systolic BP (per 1 mmHg) 1.013 (0.999–1.029) 0.078 – –
Diastolic BP (per 1 mmHg) 0.978 (0.956–1.001) 0.064 – –
Pulse pressure (per 1 mmHg) 1.022 (1.002–1.041) 0.030 1.039 (1.012–1.068) 0.005
Body mass index > 27 kg/m2 1.362 (0.507–3.662) 0.540 – –
Laboratory parameters
Albumin (per 1 g/dL) 0.147 (0.045–0.481) 0.002 0.128 (0.028–0.598) 0.009
Fasting glucose (mg/dL) 1.006 (1.001–1.012) 0.030 0.998 (0.989–1.006) 0.576
Triglyceride (per 1 mg/dL) 1.000 (0.996–1.003) 0.763 – –
Cholesterol (per 1 mg/dL) 0.996 (0.987–1.005) 0.428 – –
HDL cholesterol (per 1 mg/dL) 0.957 (0.926–0.990) 0.011 0.964 (0.920–1.011) 0.129
LDL cholesterol (per 1 mg/dL) 1.003 (0.989–1.017) 0.698 – –
Cholesterol/HDL (per 1.0) 1.139 (0.896–1.448) 0.288 – –
LDL/HDL (per 1.0) 1.485 (0.976–2.259) 0.065 – –
Hematocrit (per 1%) 1.132 (1.021–1.256) 0.019 1.194 (1.048–1.359) 0.008
Calcium (per 1 mg/dL) 1.016 (0.649–1.592) 0.943 – –
Phosphate (per 1 mg/dL) 1.008 (0.749–1.357) 0.957 – –
Calcium-phosphate product 1.003 (0.976–1.032) 0.812 – –
Uric acid (per 1 mg/dL) 1.019 (0.806–1.288) 0.875 – –
PTH (per 1 pg/mL) 1.000 (0.999–1.000) 0.358 – –
C-reactive protein (per 1 mg/L) 1.116 (0.866–1.439) 0.395 – –
Kt/V (per 1.0) 1.703 (0.386–7.515) 0.482 – –
OR = odds ratio; CI = confidence interval; BP = blood pressure; HDL = high-density lipoprotein; LDL = low-density lipoprotein; PTH =
parathyroid hormone.
hematocrit. It is known that certain hemorheologic fac-
tors such as hematocrit, as well as blood and plasma
viscosity, are associated with clinical manifestations of
atherosclerosis by promoting endothelial damage and
diffuse intimal thickening during the atherosclerotic
process [23–25]. Another reasonable explanation is
that a high hematocrit level might be a consequence
of using high doses of erythropoietin. In an animal
model, continuous administration of erythropoietin
in mice resulted in an increased size of the atheroscle-
rotic lesion [25]. Thus our results show an association
between elevated hematocrit and ABI < 0.9.
It is well recognized that diabetes is a risk factor 
of peripheral artery disease [26,27]. In the present
study, although DM was a strong predictor for PAOD
in univariate analysis, the statistical impact was no
longer significant in multivariate analysis. The impact
of DM might be confounded by malnutrition, such as
low levels of serum albumin. The multivariate analy-
sis demonstrated that PAOD was independently asso-
ciated with low serum albumin level in our study. 
A low serum albumin level has been regarded not
only as indicative of a malnutrition status but also
the presence of chronic inflammation [28]. Chronic
inflammation is recognized as a risk factor for 
atherosclerosis [29,30].
Secondary hyperparathyroidism and the effect of
calcium, phosphorous and the calcium-phosphorous
product has been reported to contribute to endothe-
lial dysfunction and vascular calcification in patients
with chronic renal failure [31,32]. In our study, these
parameters did not seem to be associated with PAOD.
A reasonable explanation is that vascular calcification
owing to secondary hyperparathyroidism and dis-
ordered calcium and phosphate homeostasis might
result in false elevation of ABI values [33]. Thus, our
result showed no correlation between serum PTH level
and PAOD.
Dyslipidemia is a well-established atherogenic fac-
tor in hemodialysis patients [34,35]. Matsumae et al
evaluated the determinants of PAOD and arterial stiff-
ness in 143 nondiabetic hemodialysis patients and
found that low-density lipoprotein cholesterol was
negatively associated with ABI and aortic pulse wave
velocity [8]. However, some studies reported the ab-
sence of an association between serum lipid levels and
PAOD [21,22]. In our study, there was no association
between serum lipid levels and ABI < 0.9, which was
consistent with Cheung et al [21] and O’Hare et al [22].
So far, whether the dialysis process or ESRD itself
promotes atherosclerosis progression remains con-
troversial. Several studies have demonstrated that
the duration of dialysis correlates well with peri-
pheral artery disease [8,22,36]. They explained their
finding by vascular calcification caused by alterations
in the metabolism of calcium, phosphate and PTH,
inflammatory alterations, oxidative stress or hyper-
homocysteinemia [3,37]. However, some studies also
showed contradicting results [21,38]. Our study
showed no significant relationship between the dura-
tion of hemodialysis and peripheral artery disease.
Further prospective studies are needed to determine
whether the duration of hemodialysis contributes to
atherosclerosis.
Falsely elevated pressure or incompressible arter-
ies at the ankle level are common among patients with
extensive vascular calcification of the lower extremi-
ties, which may occur in patients with diabetes or on
hemodialysis [9,10]. The prevalence of PAOD may be
underestimated when the criteria of ABI < 0.9 was
used because many of our patients had DM (40.9%).
In our study, 13 patients (5.8%) had ABI ≥ 1.3. The
abnormally high ABI value or incompressible arteries
had been interpreted as the presence of medial artery
calcification. Hemodialysis patients with abnormally
high ABI have poor prognosis for all-cause and 
cardiovascular mortality [9].
There are several limitations to our study. The study
subjects were enrolled from only one regional hospi-
tal and the selection of patients was rather restricted.
Therefore, generality of the results is limited. In addi-
tion, because the design of the study is observational, it
is susceptible to selection bias. We minimized this bias
by enrolling all hemodialysis patients in our dialysis
clinics and statistically adjusting for several variables
that may influence peripheral artery disease. Finally,
this was a cross-sectional study and thus we cannot
evaluate the predictors of peripheral artery disease.
A prospective trial is needed to determine the predic-
tors for the progression of peripheral artery disease.
In conclusion, this study demonstrated the associ-
ated risk factors of peripheral artery disease among
hemodialysis patients in southern Taiwan. ESRD
patients of advanced age and with increased pulse
pressure, increased hematocrit and decreased serum
albumin level had a relatively high risk for PAOD
and patients with DM had a relatively high risk for
ABI ≥ 1.3.
ABI in hemodialysis patients
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探討一醫院血液透析病人不正常踝臂血壓比的相關
危險因子
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踝臂血壓比可做為周邊動脈疾病的指標，且可用來預測血液透析病人的死亡率。但在
高末期腎臟病盛行率的南台灣卻鮮少探討。此篇文章即探討一醫院血液透析病人周邊
動脈疾病的盛行率及相關危險因子。除了 6 個病人拒絕及 4 個心房顫動的病人，我們
收集了一間區域醫院所有常規血液透析病人，共 225 個病人。我們以 ABI-form 
(Colin VP 1000) 的儀器來為病人測量踝臂血壓比。踝臂血壓比 < 0.9及 ≥ 1.3 的盛
行率分別為 15.6% 及 5.8%。年紀較大 (p = 0.027)，脈壓增大 (p = 0.005)、血比容
增加 (p = 0.008) 及白蛋白降低 (p = 0.009) 與踝臂血壓比 < 0.9 呈有意義相關。另
外，糖尿病則與踝臂血壓比 ≥ 1.3 有相關 (p = 0.019)。本篇文章提供在一醫院血液透
析病人周邊動脈疾病的相關危險因子。其年紀較大，脈壓較高，血比容較高及白蛋白
降低為踝臂血壓比 < 0.9 的危險因子，而糖尿病則為踝臂血壓比 ≥ 1.3 的危險因子。
關鍵詞：踝臂血壓比，血液透析，周邊動脈疾病
(高雄醫誌 2008;24:473–80)
